ImmunoGen, Inc. Hires Sandra E. Poole as Senior Vice President of Technical Operations
September 15 2014 - 8:30AM
Business Wire
ImmunoGen, Inc. (NASDAQ: IMGN), a
biotechnology company that develops targeted anticancer therapies
using its antibody-drug conjugate (ADC) technology, today announced
the appointment of Sandra E. Poole as Senior Vice President,
Technical Operations. Ms. Poole brings to ImmunoGen more than 25
years of experience related to the development and manufacturing of
innovative biopharmaceuticals, most recently as the senior vice
president of biologics manufacturing at Genzyme. She reports to
Daniel Junius, President and Chief Executive Officer of
ImmunoGen.
“Sandra joins ImmunoGen in a newly established position that
reflects our advancing, broadening pipeline and escalating
preparations for later-stage clinical trials,” commented Mr.
Junius. “She brings extensive experience successfully leading
complex biologics operations, integrating functions that include
process development, production, and quality assurance.”
Prior to ImmunoGen, Ms. Poole had a 15-year career with Genzyme
that spanned a wealth of bio-manufacturing-related functions with
increasing responsibility, including heading up technology
development, overseeing the construction, start-up, tech transfer
and approval of a fully integrated manufacturing operation in
Belgium and, most recently, leading Genzyme’s global network of
biologic manufacturing sites.
Prior to joining Genzyme in 1999, Ms. Poole oversaw process
development and played a key role in establishing technical
operations at Canadian-based Biomira, Inc. She holds both a Master
and a Bachelor of Applied Science degree from the University of
Waterloo (Canada) in chemical engineering and also completed the
executive program in business management at the Massachusetts
Institute of Technology Sloan School of Management.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The
Company’s ADC technology uses tumor-targeting antibodies to deliver
an ImmunoGen cell-killing agent specifically to cancer cells; the
Company has also developed antibodies with anticancer activity of
their own. The first product with ImmunoGen’s ADC technology is
Roche’s Kadcyla®. ImmunoGen has three wholly owned product
candidates in clinical testing with additional compounds in
clinical testing through the Company’s partnerships with Amgen,
Bayer HealthCare, Biotest and Sanofi. More information about
ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
For Investors:ImmunoGen, Inc.Carol Hausner,
781-895-0600info@immunogen.comorFor Media:Pure Communications,
Inc.Dan Budwick, 973-271-6085
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024